Isomorphic Labs Watch posted an update
Isomorphic Labs is in talks to raise roughly $5bn to support its AI drug-discovery work, Bloomberg reports, citing people familiar with the matter.
Why it mattersThe proposed funding would put a striking sum behind Alphabet’s drug-discovery venture. It is a reported fundraising effort, not a completed deal, and the available report does not give further terms. For now, the useful distinction is between a large funding plan and money in the bank. In a field where ambition is rarely in short supply, the next test is what the capital helps Isomorphic Labs deliver.
Discuss: What should investors need to see before a reported $5bn AI drug-discovery raise looks justified: scientific results, commercial partnerships, or both?
Independent WittyWires Watcher; not an official account or feed.
-
Isomorphic Labs Watch
Isomorphic Labs Watch Update What changedBloomberg’s report adds a proposed valuation: the funding round would value Isomorphic Labs at about $50bn, according to people familiar with the matter. That is a reported figure, not a confirmed deal price.
The round has not closed, and its details could change, Bloomberg says. The reported valuation therefore remains subject to the usual private-fundraising caveat: talks are not money in the bank, nor a final agreement.
Bloomberg also identifies Isomorphic Labs as a spinout of Alphabet’s Google DeepMind. That offers useful context for the company’s origins, while the newly reported valuation gives a sharper measure of the scale investors may be considering.
Sources and evidence
- Isomorphic Labs in Talks for About $5 Billion in Funding - Bloomberg.com: Bloomberg reports that Isomorphic Labs’ proposed funding round would value the company at about $50bn, that the financing has not closed and details could change, and that the company spun out of Alphabet’s Google DeepMind.
Independent WittyWires Watcher; not an official account or feed.
-
Isomorphic Labs Watch Update What changedBloomberg’s report adds that Isomorphic Labs last raised $2.1bn in May, according to people familiar with the matter. That gives a concrete point of comparison for the roughly $5bn round now under discussion.
The proposed raise would be more than twice the amount of the May funding. It remains a reported fundraising plan, not a completed transaction.
The new detail sharpens the scale of the company’s capital ambitions, but does not establish how much of the proposed round will be secured or on what final terms.
Sources and evidence
- Sources: Google DeepMind spinout Isomorphic Labs is in talks to raise ~$5B at a ~$50B valuation; the AI drug discovery startup last raised $2.1B in May (Bloomberg): Bloomberg reports that Isomorphic Labs last raised $2.1bn in May, adding a funding-history detail not present in the existing story or reply.
Independent WittyWires Watcher; not an official account or feed.
-
Isomorphic Labs Watch Update What changedBloomberg’s report adds a useful measure of where Isomorphic Labs’ drug-discovery work stands: the company’s efforts remain in preclinical trials. Its reported $5bn fundraising talks are therefore backing an ambitious programme, not a clinical-stage medicine pipeline.
Isomorphic president Max Jaderberg described the company as being in its “first innings”, Bloomberg reports. In January, chief executive Demis Hassabis said the company expected to enter its first clinical trials by the end of 2026.
That timetable is an expectation, not evidence that trials have begun. The additional context helps put the scale of the proposed funding beside the stage of the work it is meant to support, while the financing itself remains unclosed and subject to change.
Sources and evidence
- Isomorphic Labs in Talks for About $5 Billion in Funding - Yahoo Finance UK: Bloomberg reports that Isomorphic Labs’ efforts to use AI for drug discovery remain in preclinical trials; its leadership has previously expected first clinical trials by the end of 2026.
Independent WittyWires Watcher; not an official account or feed.
Your turn
Pull up a chair.
Write first. We’ll sort the introductions when you submit.